Dec. 2, 2005
|
|
6:30-8:30 pm |
Register and collect the foreign guest materials and join in an
informal reception (Leader Hotel & Resort) |
|
Dec. 3, 2005 |
|
8:00 am |
Registration (Taipei Youth Activity Center 6F) |
Session 1: Drug
Discovery and Development
|
|
8:30¡V9:00 am |
Opening remark |
|
9:00¡V9:10 am |
Introduction
Dr.
Yu-Sheng Chao,
Director, Division of Biotechnology & Pharmaceutical Research,
National Health Research Institute |
|
9:10¡V10:00 am |
Keynote speaker
Dr. Yale Mitchel,
Executive Director, Clinical Research Merck & Co., Inc., USA |
|
10:00-10:15 am |
Morning break |
|
10:15-10:20 am |
Introduction
Dr.
Jen Chen,
President, Genovate Biotechnology Co., Taiwan |
|
10:20-11:00 am |
Dr. Frank Martin,
Chief Scientific Officer, iMEDD, Inc, USA |
|
11:00-11:05 am |
Introduction
Prof.
Song-Nan Chow,
President of Taiwan Foundation for the Development of Biomedical
Technology |
|
11:05-11:45 am |
¡§GSK
HPV Vaccine Development : Status and Future perspective¡¨
Dr. Marie-Therese Martin,
Associate Director, Late Development HPV Vaccine, Belgium |
|
11:45 am-12:15 pm |
Prof. Ann-Lii Cheng,
College
of Medicine, National Taiwan University,
Taipei, Taiwan |
|
12:15 pm-1:25 pm |
Mid-day break |
|
Session 2 : Novel Anticancer Therapeutics (I) |
|
1:25-1:30 pm |
Introduction
Prof.
Ji-Wang Chern,
School
of Pharmacy, National Taiwan University |
|
1:30-2:10 pm |
¡§Development of Factor VIIa
Inhibitors for the Treatment of Cardiovascular Disease¡¨
Dr. Wendy B. Young,
Senior Director, Medicinal Chemistry, Celera Genomics, California,
USA |
|
2:10-2:15 pm |
Introduction
Prof.
Cherng-Chyi Tzeng,
Kaohsiung Medical University |
|
2:15-2:45 pm |
¡§Targeting Akt Signaling in Cancer Therapy. Opportunities and
Challenges¡¨
Prof. C. S. Chen, PhD,
College of Pharmacy, Ohio State University, Ohio, USA |
|
2:45-3:15 pm |
¡§Immunomodulators as potential liver protectants for treating of
hepatitis¡¨
Dr. Edwin Wu,
President and CSO, Jenken Biosciences, Inc., USA |
|
3:15-3:30 pm |
Afternoon Break |
|
Session 3: Novel Anticancer Therapeutics (II) |
|
3:30-3:35 pm |
Introduction
Prof.
Jih-Hwa Guh,
School
of Pharmacy, National Taiwan University |
|
3:35-4:15 pm |
¡§The Development of Novel
Aminopyrazoles with Anti-angiogenesis and Tumor Cells
Anti-proliferation Activities for Cancer Therapy¡¨
Dr. Chih Yung Ho,
R. W. Johnson Pharmaceutical Research Institute, USA |
|
4:15-4:20 pm |
Introduction
Prof.
Jih-Hwa Guh,
School
of Pharmacy, National Taiwan University |
|
4:20-5:00 pm |
"Development of Recombinant Desirudin ¡V an Anticoagulant Found in
Leech"
Dr.
Cheng Der Tony Yu,
President & Chief Scientific
Officer, Canyon Pharmaceuticals, Inc., Hunt Valley, Maryland, USA |
|
5:00 pm |
Adjourn |
|
6:00-7:00 pm |
Round Table Discussion: Cultivation of Drug Development in Taiwan
Chairman:
Prof.
Song-Nan Chow, M. D,
President of Taiwan Foundation for the Development of Biomedical
Technology
|
|
7:00¡V09:30 pm |
Welcome Banquet
(Sheraton Taipei Hotel 17F for invited speakers only) |
|
Dec. 4, 2005 |
|
8:00 am |
Registration (Taipei Youth Activity Center 6F) |
|
Session 4: Novel Anticancer Therapeutics
(III) |
|
8:30-8:35 am |
Introduction
Prof. C.M. Tseng,
National Taiwan University |
|
8:35-9:15 am |
"Targeted anticancer therapy - the Glivec story"
Dr. Alex Matter, M.D.,
Director, Novartis Institute for Tropical Diseases |
|
9:15-9:20 am |
Introduction
Prof.
Ding-Shinn Chen,
Dean, College of Medicine, National Taiwan University |
|
9:20-10:00 am |
Dr. John Kavanagh, MD,
Houston, USA |
|
10:00-10:15 am |
Morning Break |
|
Session 5: Novel Anticancer Therapeutics (IV) |
|
10:15-10:20 am |
Introduction
Prof.
Ling-Wei Hsin,
School
of Pharmacy, National Taiwan University |
|
10:20-11:00 am |
¡§Farnesyltransferase Inhibitors as Cytostatic Agents¡¨
Dr. Laurence I. Wu,
Vice President, Drug Discovery, PharmaEssentia Corp, Taipei, Taiwan. |
|
11:00-11:05 am |
Introduction
Prof.
An-Rong Lee,
National Defense Medical Center |
|
11:05-11:45 am |
¡@
¡@
¡@
|
|
11:45 am-12:15 pm |
¡§Development of Targeted Delivery¡¨
Dr. Keelung Hong,
Chairman & CEO, Taiwan Liposome Company, Taipei, Taiwan |
|
12:15¡V1:15 pm |
Mid-day break |
|
Session 6: Recent Development of Antiviral
agents: |
|
1:15¡V1:20 pm |
Introduction
Dr.
Ko-Chung Lin,
Pharmaessentia Corp, Taiwan |
|
1:20-2:00 pm |
Prof. George K.K Lau, MD, PhD,
Assistant Dean of Faculty of Medicine, The University of Hong Kong,
China |
|
2:00-2:05 pm |
Introduction
Dr.
Ko-Chung Lin,
Pharmaessentia Corp, Taiwan |
|
2:05-2:45 pm |
Dr. Yibin Xiang,
Senior Director, Medicinal Chemistry, Genzyme Corporation, USA |
|
2:45-3:15 pm |
Dr. Kuei-Ying Lin,
Group Leader, Drug Discovery, Gilead Sciences, Inc., California, USA |
|
3:15-3:30 pm |
Afternoon Break |
Session 7:
Development of Antidepressant Therapeutics
|
|
3:30-3:35 pm |
Introduction
Prof.
Fan-Lu Kung,
School
of Pharmacy, National Taiwan University |
|
3:35-4:15 pm |
"Discovery and Development of a Non-peptide Delta Receptor Agonist
DPI-289: a Potential Antidepressant of Fast Onset of Action"
Dr. Kwen-Jen (Ken) Chang,
President-Asia Pacific Operations & Chief Science Officer, Enhance
Biotech Inc., USA |
|
4:15-4:20 pm |
Introduction
Prof.
C. S. Chen, PhD.,
College of Pharmacy, Ohio State University, USA) |
|
4:20-5:00 pm |
Dr. Tung-Ping Su
Yang
Ming Medical University, Taiwan
Dr. Yao-Chang Xu,
Head, Discovery Chemistry Research, Lilly Research Laboratories
Lilly Corporate Center, U.S.A |
|
5:00 pm |
Adjourn |
|
6:00 pm¡V9:30 pm |
Farewell Banquet (Hai Pa Wang) |
|
Dec. 5~6, 2005 |
|
Symposium excursion- two days tour to Hualien |